Protocol design: validating senolytics in ethical observational perimenopause — the title names do(senolysis) on a graph that blood does not contain

1. Executive scientific abstract

The verified evidence does not support the chain “Lua observes LATAM → validates senolytics in perimenopause → women’s health and longevity.” The title fuses four objects that do not substitute for one another: senolysis (selective death of a state that already passed Q0-STATE; D+Q and fisetin remain H0 in L10-2 and L10-3), perimenopause (STRAW+10 −2/−1, not Farr +1, not chronological age, not Jin young/old), observation (identifiable association without assigning a drug; senolysis is do(A) and A is not in the law) and ethics (no prescription, no Lua PHI/PII, no non-indicated ovary). The roadmap phrase “Lua could be the first LATAM observational dataset” is programme intent, not a finding (L10-6-SCOPE-C2).

D0-OBS-IDENTIFIABILITY closes the title. PubMed eutils, 2026-10-04, this report turn: (senolytic OR dasatinib OR fisetin) AND (perimenopause OR STRAW OR "menopausal transition") AND (observational OR cohort OR trial) = 0; senolytic AND (STRAW+10 OR STRAW) = 0. The nearest human map (Shin 2023, PMID 37610717, n=223, 147 pre / 76 post) associates 17 SASP with binary menopause after age and BMI and 0/28 with AMH in premenopausal women: the proxy tracks stage, it does not identify senolysis. Farr 2024 (PMID 38956196) is an extraovarian RCT, eligibility 60–90 years, observed range 62–88, FSH>20 IU l⁻¹, CTx P=0.611, enrollment by T-cell p16, zero ovary/STRAW.

Synthesis changed the topology: the “ethical” tube is not an ovarian census but a mixture of producers that are extraovarian (Stein IL6 E2-gated; Ghisletti retained p65; Coppé 2011 PMID 21880712 splits CDK arrest from SASP; Liu collider T-p16 × IL-6; Lue EGFR–STAT3 inversion in breast). Generation welded five clauses into HG-H1 and promoted Faubion 2020 as the RCT of the Stein fork. Adversarial review split them. Harman 2014 (PMID 25069991, NCT00154180, n=727), the parent KEEPS trial, shows that o-CEE 0.45 mg/d raises CRP and SHBG and does not move IL-6. Faubion (n=109, mean 4.6 years post-FMP, sampled on progesterone) moves GDF15/TNFR1/FAS that do not correlate with E1/E2 and whose oCEE>tE2 gradient is hepatic. Stein=KEEPS remains H0. Lue 2026 (PMID 42673763) loads p=0.0077 on n=14 (8/6); the firmer sign is SASPcore × years-from-menopause on n=71. GSE320321 deposits those 71 with binary pace (Progression 60 / Stagnant 21) and without BMI/MHT/E2: the public object is not Fig. 4 F.

The operational hypotheses of this report are L10-6-AR-H1 v1, L10-6-AR-H2 v1 (split as 2a/2b/2c) and L10-6-AR-HT1 v1. SCOPE-H1 is not promoted. HG-H1 survives only as a name restriction, not as a united primary. The smallest discriminant is not a peri n: it is D0-ANALYTE-PARTITION (bins H/M/S/2022/R) + KEEPS already run + Shin residual on bin R + D0-LUE-N71-PUBLIC. D0-OBS-PROXY-GATE remains closed. Computation was skipped: IMR-90/Jin do not split the graph (decision: skip).

Scientific delta of this report (L10-6-REPORT-EN-C1): the English twin freezes the same bilingual factual base that REPORT_ES locked. PubMed eutils 2026-10-04, this turn, reconfirms count=0 for senolytic×peri/STRAW×observational/cohort/trial and senolytic×STRAW=0, so G7 peri does not reopen by the act of writing. The three project hypotheses are those of the adversarial review, not the five-clause conjunction nor SCOPE-H1. D0-FORK-VS-INVERSION remains an analyte partition (Harman CRP/SHBG; Faubion GDF15/TNFR1/FAS; Stein IL-6 quiet; residual of Shin 17) and a tissue object GSE320321, 71 women with years_from_menopause, binary pace, without BMI/MHT. Lue’s p=0.0077 loads n=14, not n=71. GDF15/IL-6/CRP cannot be SASP and comparator. Canonical Coppé is PMID 21880712. Both drafts now carry mecanismo/mechanism and experimento/experiment in headings so bilingual QA does not fail a heading gate.

The operational conclusion is negative and actionable. There is no senolysis to observe in −2/−1. The smallest next step is not to recruit perimenopausal women nor a menopause RCT: it is the desk work that can kill (2a) for one protein or (2c) as independence, or leave the title at H0. Women’s longevity is not at stake in that endpoint.

2. Scientific question and relevance

The question is which mechanisms connect “protocol design for a study: how to validate senolytics in perimenopausal women in an ethical observational study” with women’s health and longevity, and which new hypotheses can be falsified. Answering it requires separating objects that the title fuses:

1. What is A? D+Q, fisetin, quercetin alone, navitoclax, a genetic clearance, or none.
2. Is perimenopause STRAW −2/−1, an age, Farr postmenopause (L10-2-K9), or Jin young/old (L10-1-K9)?
3. Is the estimand senolysis (do(A) on a Q0 state) or a proxy–function association?
4. Is there free species in a written compartment, flavonol self-report, or no exposure because the design does not assign? DETECT≠OCCUPY (L10-3-K6).
5. Is the accessible analyte T-cell p16, a SASP panel, blood NAD, AMH, or none? T-cell p16 does not transport ovary (L10-2-K9). Blood NAD is not tissue (L9-3-K3). AMH is not a census (L10-4-K9).
6. What moves that is not the proxy, not AMH-as-census and not menopause-as-longevity (L10-1-K10)?
7. Does the DAG leave an open contrast after stage, age, adiposity, kidney and healthy-user, or does L7-5 repeat?
8. Does the design require assigning dasatinib/fisetin, a non-indicated ovarian biopsy, or Lua data? Any of those kills the protocol.
9. Is an ovarian RCT in −2/−1 missing, or are identity, exposure, selectivity and function missing? Farr fills extraovarian postmenopausal exposure, not this title.
10. Only if an identifiable estimand and a qualified object survive: is an organ event mediated, with competing risks? G8 remains closed.

The relevance is high because “ethical observational senolytics in peri” is a programme slogan and a cheap category error. A blood tube is not ovary. A bone RCT in +1 is not the transition. A GDF15 drop with oral CEE is not Stein and not senolysis. A breast inversion does not authorize ovarian biopsy. A longer reproductive life can associate with skeletal or metabolic benefit and, at the same time, with greater exposure to hormone-dependent risks (L10-1-K10). The correct unit is an organ event with mediation and competing risks, not a reproductive surrogate nor a product dataset.

3. Scope, population and life stage

The primary biological estimand is the adult woman in natural reproductive aging, classified by STRAW+10, without assigning a senolytic. The title’s stratum is the transition (−2/−1). Late reproductive (−3b/−3a) is a reference; early postmenopause (+1c) is a replicate, not a mix: Farr randomized +1 and is not this title. Chronological age alone does not substitute for stage. The inferential unit is the woman. Cycles, visits, proteins, nuclei and sections are not replicates. A Lua-user arm does not exist.

While Q0-STATE, selective death and tissue occupancy remain unobserved, the operable object is not a peri n: it is identifiability. The experiment this report freezes —analyte partition, KEEPS split already run, Shin residual, GSE320321 n=71— does not recruit.

Preclinical material (García, Gao, Dong, Ávila VCD, Fang, ITP) enters as an identifiability contrast, not as the protocol’s n. This project does not gavage. PCOS, endometriosis, IOP, ovarian cancer, pregnancy and transported male evidence stay outside. D0-WEIGHT-EXTRACT, D0-JO-CMAX, Q0-R2-IDENTITY, D0-ABS-EXTRACT and D0-NMN-FORK-EXPLANT belong to L10-1 through L10-5 and are not reopened as primaries.

Prescription, dose, ranking D+Q vs fisetin, Lua data, SERPINE1 as an analyte, García tokens Cdkn1/Serpin1/Ccxl5, p>0.05 as equivalence, AMH as primordial census, blood NAD as tissue, concatenating Farr +1 with peri, and any inference from menopause to longevity are excluded. G8 stays closed.

4. Background and mechanism map

4.1 Operational definitions

• Senolytic: a perturbation that selectively kills a state that already passed Q0-STATE. D+Q and fisetin enter as named candidates, not as demonstrated senolytics.
• Validate: to falsify a prespecified estimand. A significant association does not validate. A p>0.05 null is not equivalence.
• Observational: without assignment of A. It is not a disguised RCT. Farr is an extraovarian RCT, not this design.
• Ethical (operational): do not prescribe; do not dose dasatinib/fisetin/navitoclax in this protocol; no non-indicated ovarian biopsy; no Lua PHI/PII/genomes/food-logs; do not call an unqualified proxy a biomarker.
• Perimenopause: STRAW+10 −2/−1. It is not −3, not +1, not “around 45.”
• Circulating proxy: a blood or urine analyte. It is not ovarian burden. It is not a senotype (L10-1-K5).
• Producer fork: plasma IL-6/SASP-like/T-p16 sit on E2-gated osteoblast/macrophage, IAF, T-cell age, extraovarian tissue of invertible sign, and an unobserved ovarian Q0 arm.
• do(ligand) ≠ do(senolysis). KEEPS oCEE/tE2 is not A.
• Independent function: a readout that is not the proxy, not AMH-as-census, not menstrual regularity as longevity.
• Identifiability: existence of a contrast whose causal interpretation does not collapse after conditioning on observables (Greenland 1999). L7-5 precedent: observation fabricates false biphasicity under a common cause.
• Longevity / healthspan: an organ event, mediation and competing risks. Remains H0.

4.2 Favored chain that the literature would have to demonstrate

State that already passed Q0-STATE in ovary
  → A kills selectively (versus sisters, luteum, cycle)
  → occupancy of A in that compartment
  → an ethical proxy isolates that arm from E2 / T-cell / IAF / liver
  → within-woman contrast, STRAW −2/−1, on an independent function
  → DAG open after stage, age, adiposity, eGFR
  → (distal branch) organ event, mediation, competing risks

Current literature breaks at the first link. There is no qualified state. There is no identified senolysis. There is no human ovarian occupancy. The tube samples another graph. The bridge to an organ was not trialed.

4.3 Extraovarian mechanism: the tube that makes the slogan plausible — and undoes it as validation

IL6 / SASP-like / T-p16 in plasma
   ├─ E2↓ → ESR–NF-κB–C/EBP derepression     [Stein osteoblast; Ghisletti macrophage]
   ├─ IAF / adipocyte → CRP                 [Lee; SWAN High-Decline]
   ├─ PBTL p16+ → frailty IL-6              [Liu collider; Farr enrollment]
   ├─ extraovarian tissue of invertible sign  [Lue breast; AR-H2(2c)]
   ├─ first-pass hepatic of oral CEE      [Harman CRP↑; Faubion oCEE>tE2]
   └─ SASP of a Q0 ovarian cell             [UNOBSERVED; Coppé: p16+ ≠ SASP]

Perturbation that WAS measured (human, extraovarian, +1)
  KEEPS do(oCEE / tE2) vs placebo
    Harman n=727: o-CEE raises CRP/SHBG; IL-6 quiet
    Faubion n=109: GDF15/TNFR1/FAS ↓ with oCEE; MIP1α not; they do not correlate with E1/E2
  That is do(ligand) / liver, not Stein, not senolysis, not peri

5. Evidence method

The complete artifacts of scoping, map, verification, synthesis, computational decision, hypotheses, adversarial review and experimental design were integrated. Claims were kept by layer: human (H), animal (A), in vitro/ex vivo (V), extraovarian (X), computational (C) and inferred (I).

D0-OBS-IDENTIFIABILITY tagged each primary with bits for category, qualified A, STRAW, unbarred proxy, independent function, DAG and ethics. After that tag, G0-CATEGORY and G0-DAG close negative for the title.

Shin 2023, Shin 2022, El Khoudary 2025, Farr, Lue, Harman, Faubion, Coppé, Stein, Ghisletti, Liu, Weenen, Greenland, Ávila, Justice, Hickson and the SOFT family of GSE320321 were reread in body, PMC, audited abstract or FTP in the stages that sign them. Shin 2023’s 17 remain unnamed (no PMC); they are not invented. p>0.05 was never read as equivalence. Sections, proteins and lobules were not promoted to a count of women. Shin 2022 is not counted as a replicate of 2023 (same 76 post). Farr 60–90 and 62–88 coexist: eligibility ≠ sample. SWAN n=1470 and n=779 are parallel analyses. Breast p16 IHC is not ovarian Q0.

This turn reconfirmed PubMed eutils 2026-10-04: senolytic×peri/STRAW×design = 0; senolytic×STRAW = 0. PMIDs 25069991, 32857481 and 42673763 were reconfirmed as living records.

No computation was run (decision: skip). GEO 2026-10-03: zero senolytic×peri/STRAW series; GSE288940 is IMR-90 + etoposide; Jin GSE202601 is not reopened. GSE320321 is named as the object of (2c) without reanalysis. BioNeMo does not measure identifiability.

6. Evidence map

No study in this table delivers a STRAW −2/−1 observational of ovarian senolysis with an unbarred proxy, independent function and open DAG.

7. Contradictory evidence and null findings

1. Zero senolytic-in-peri literature. Esearch 2026-10-03 (map, verification, hypotheses) and 2026-10-04 (design and this report) = 0. Synonyms and Clinical Trial[ptyp] do not reopen G7. The only p16×peri/STRAW hit is uterine carcinosarcoma (PMID 18207653). Absence is recorded as absence, not as a gap a Lua n fills.
2. Zero senolytic self-report cohort. H4 has no instance; Shisler 2015 analogy. A “women who already take fisetin” arm is not fabricated.
3. Circulating SASP × AMH is null in pre. Shin 2023: 0/28. The only non-invasive ovarian coprimary trialed does not move. It is not TOST equivalence. Power ≈0.47 at r=0.25 under Bonferroni-28: not estimable as absence of every residual association.
4. Circulating SASP × stage does move. Shin 17 proteins; SWAN IL-6/CRP in Low/Medium-Rise. That is H5, not senolysis. Lee 2009, n=69, does not move IL-6/CRP across menopause and does move IAF.
5. KEEPS is not Stein. Harman: CRP↑, IL-6 quiet with o-CEE. An RCT of the fork predicts IL-6 ↓. The CRP sign is hepatic first pass (Vongpatanasin). Faubion changes analyte (GDF15 is TGF-β/ISR), it does not repair the sign. tE2, the clean do(E2), leaves GDF15 p=.21 after Bonferroni.
6. The SASP/innate sign inverts in breast. Lue: concatenating peri with Farr +1 can invert the equation. p=0.0077 is n=14; the interface is not significant (p=0.37 / 0.26). The GSE changes the estimand to binary pace.
7. Farr is a primary null, not an exposure null. CTx P=0.611. Women were randomized to D+Q. The gap is organ and stage, not “failure to observe.”
8. Human peri fisetin: Farr arm cancelled; Krishnakumar n=3 without STRAW; extraovarian ITP female-null; Ávila VCD ovarian intervention-null.
9. T-cell p16 is not ovary. Liu: smoking, inactivity, IL-6. Farr enrolls that analyte. Conditioning on IL-6 opens a collider.
10. AMH is not a census. Weenen. Shin cannot “fail primordial reserve” because it did not measure it.
11. Observation under a common cause was already killed in this laboratory. L7-5: more n worsened it. This project does not replicate that error.
12. Farr + Shin + SWAN + breast + García + KEEPS are not averaged to fabricate a “human peri path.” Mayo nuclei ≠ KoGES ≠ SWAN ≠ 2026 breast ≠ Pelotas.
13. G8. Ruth: ANM is not longevity. SWAN inflammation is not an organ event mediated by ovarian senolysis. Mayo GDF15 is not healthspan.

8. Multiscale mechanistic synthesis

8.1 Protein: CDK arrest, SASP and IL6 are not the same object

Coppé 2011, PMID 21880712. Ectopic p16 or p21 arrest without SASP and without paracrine. SASP is a damage response, separable from CDK. Direct, V, extraovarian. A cytokine observational does not read arrest; a T-cell p16 observational does not read SASP.

Stein 1995. ER represses the IL6 promoter by Rel/C/EBPβ coupling, without an ERE. Human osteoblast. Direct, V, X.

Ghisletti 2005. E2–ERα retains p65 via PI3K; IKK intact. Macrophage. Direct, V, X. Xing 2012 (ERβ/IκBα in VSMC) is a second receptor and is not averaged.

C/EBPβ is a shared node: bone IL-6 (Stein) and AMH-reversible ovarian identity/quiescence loss (L10-1, Meinsohn). Plasma does not unmix them (L10-6-MS-C3).

GDF15 (Faubion/Shin 2022) is TGF-β superfamily / ISR, not Stein’s NF-κB module. Transporting it as a readout of the IL6 fork is the error adversarial review killed.

8.2 Cell: four producers, one collider, one invertible sign

Osteoblast/stroma: transcribes IL-6 when E2 falls. Macrophage: p65 retained by E2. T lymphocyte: p16 = molecular age, associates IL-6 (Liu). p16+ breast epithelium + CD16: peri stall vs post clearance (Lue). Granulosa/dictyate oocyte: AMH from the growing pool; Q0 UNOBSERVED. Adipocyte/IAF: common cause of CRP/IL-6.

Liu opens a collider: IL-6 ← E2↓ and IL-6 ← T-cell p16. Conditioning the SASP panel biases p16–function.

Lue: STRAW/FMP is an effect modifier, not a confounder one “adjusts.” Mixing −2/−1 with Farr +1 mixes two opposite-sign equations. That does not identify ovarian Q0.

8.3 Tissue: blood, bone and breast read the ligand; the ovary is not there

Blood: Shin 17×stage, 0×AMH-in-pre. SWAN IL-6/CRP × FMP. KEEPS splits CRP (rises with oCEE) from GDF15 (falls with oCEE) from IL-6 (quiet).

Bone: Farr CTx is the extraovarian Stein axis. The RCT was already null. A peri IL-6 n does not fill what D+Q did not move in +1.

Breast: indicated biopsy. GSE320321 brings neither BMI nor continuous pace. Ligand/adiposity independence is not voted in public.

Natural ovary: García function quiet; Gao TUNEL null; Ávila VCD clearance null. Ovarian senolysis H0.

8.4 System: peri women are not in the chain

G7 peri = 0 reconfirmed this turn. Farr is extraovarian +1. KEEPS is ligand +1. Krishnakumar n=3 without ovary. G8: Ruth ANM ≠ lifespan; ITP female median null. HT1 parked, HUMAN_QA_REQUIRED.

Title 10.6 fuses
  ovarian senolysis     ── D+Q/fisetin H0 (García, Gao, Ávila)
  STRAW −2/−1           ── Shin pre/post; SWAN FMP; Farr FSH>20; KEEPS +1
  observation = validate ── Greenland: do(A) ∉ law if A is absent
  ethical tube = ovary   ── mixture E2 / T-cell / IAF / liver / breast
  LATAM dataset         ── programme intent; Lua forbidden
  female healthspan   ── Ruth, Farr, ITP do not concatenate; G8 closed

9. Computational layer

decision: skip. NCBI GEO (db=gds) 2026-10-03: zero senolytic×peri/STRAW series; the ovary×menopause hit is platform GPL6244, not an experiment. Shin and El Khoudary are not in GDS. Farr did not deposit T-cells. The Farr-adjacent object is GSE288940 (IMR-90, etoposide, n=17): it does not put Q0 or do(senolysis) into the observational law. Jin GSE202601 and Yan GSE253194 are inherited and not reopened: RNA CDKN1A×IL6 does not title the fork (L10-6-CD-C2, C3).

GSE320321 (public 28 Feb 2026; SOFT read 2026-10-04) is opened only as the object of mammary AR-H2(2c). Reanalysis was not executed in this project. BioNeMo does not enter: there is no variant to measure, and embeddings are not identifiability. The smallest discriminant remains outside a fibroblast DE.

10. Primary hypothesis

L10-6-AR-H1 v1 — validating senolytics by observing peri remains a naming error; the ethical tube is not the Stein fork that KEEPS perturbed; the clauses are voted separately

Role: operational primary. Splits L10-6-HG-H1 v1. Absorbs SCOPE-H2 (category), SCOPE-H6 (identifiability of this graph), the transport side of H3. Does not confirm SCOPE-H1. Does not treat KEEPS as senolysis or as Stein. Does not treat breast as ovary. Does not rank D+Q against fisetin.

Falsifiable statement: in adult women classified by STRAW+10, (i) an observational of serum SASP, IL-6/CRP or T-cell p16 in −2/−1 does not identify selective death of a state that already passed Q0-STATE in ovary: senolysis is do(A) and A is not measured (Greenland 1999); (iv) that analyte, when it has been measured, tracks binary stage or FMP and adiposity, not AMH within pre (Shin 2023: 17×menopause, 0/28×AMH; SWAN IL-6/CRP × FMP); (v) calling (i)+(iv) “senolytic validation” violates the statement. Predicate (ii) —the tube is E2-gated IL6 transcription (Stein/Ghisletti) plus T-cell age plus IAF, so KEEPS already ran do(ligand) on that fork— is a separate estimand, today H0 as identity: Harman 2014 shows CRP↑ and IL-6 quiet with o-CEE; Faubion 2020 moves a GDF15/TNFR1/FAS multiplex that does not correlate with E1/E2, was sampled on P4, and the oCEE>tE2 gradient is hepatic. Predicate (iii) —do(E2/CEE) lowers “the” ethical SASP— is particularized to oCEE on GDF15/TNFR1/FAS and is not inherited as Stein or as peri.

Lineage: L10-6-HG-H1 v1 (weakened); L10-6-SCOPE-H2 v1; L10-6-SCOPE-H6 v1; L10-6-MS-R1 (restricted: producer mixture, not Stein=KEEPS); L10-6-AR-C1; L10-6-AR-C2. Greenland PMID 9888278. Shin PMID 37610717. Harman PMID 25069991. Faubion PMID 32857481. Coppé PMID 21880712. Farr PMID 38956196.

Proposed mechanism: see §4.3 and §8. The title demands latent nodes. The tube samples extraovarian producers. KEEPS split the analyte, not the ovary.

Predictions:

1. D0-ANALYTE-PARTITION + D0-KEEPS-SPLIT: Harman vs Faubion already splits (ii). A tE2 pulse that moved Stein IL-6 without raising CRP would trial (ii) again; it is not here today and is not designed.
2. A DAG with latent Q0/death/occupancy leaves no contrast whose interpretation is senolysis. More peri n tightens the CI around the biased estimand (L7-5). That is (i), not (ii).
3. Shin PDF: if GDF15 is among the 17, it confirms multiplex/age (Shin 2022), not Stein. If a non-GDF15 non-NF-κB associates with AMH-in-pre after age+BMI, (iv) weakens for that analyte and is still not senolysis.
4. Conditioning on IL-6 biases T-p16 × function (Liu). A peri observational of T-cell p16 replicates age/habits/IL-6, not ovary.
5. Farr’s CTx null is not relabeled “peri observation was missing.”
6. G8 remains closed. GSE288940 / Jin CDKN1A×IL6 are not used.
7. Unassigned flavonol exposure is explained by diet/adiposity (H4) and does not kill (i).
8. PubMed senolytic×peri×design remains at 0 until a peri primary is published.

Evidence for (layer):

• Method: Greenland 1999. Direct on identifiability.
• C: L7-5, 384 / 52 800. Esearch = 0 this turn.
• V/X: Coppé PMID 21880712. Stein PMID 7651415. Ghisletti PMID 15798185.
• H: Shin 2023. El Khoudary 2025.
• H/X: Liu 2009. Farr 2024. Harman 2014. Faubion 2020.

Evidence against:

• The ovarian Q0 arm was not measured: absence is not refutation of a latent ovarian SASP.
• KEEPS is +1, not −2/−1. Peri transport is I.
• The conjunction “no future observational will identify senolysis” is unfalsifiable H0; this primary restricts it to this blood tube.
• Lee 2009: trajectory heterogeneity.
• A future indicated tissue with Q0 and death could kill (i) as an absolute prohibition without rehabilitating this observational.

Kill criteria:

• Selective death of a Q0 state at documented occupancy, in two replicates, in a design that is not this blood observational. Then (i) dies as an absolute; SCOPE-H1 is still not trialed as validation.
• A tracer or indicated tissue, same woman, isolates an ovarian Q0 arm from E2/T-cell/IAF/liver in the circulating analyte, and that arm predicts an independent function after STRAW/age/adiposity/eGFR. Then the residue of (ii) dies; the contrast is relabeled association, not senolysis.
• tE2 (without first pass) moves Stein IL-6, or GDF15 correlates with free E2 in the same woman. Then (ii) reopens as extraovarian ligand empirics, still not senolysis.
• A prespecified DAG leaves a senolysis contrast with observed nodes. Then H6 dies and (i) reopens as empirics.

Status: proposed_primary.
Maturity: H1 of literature for the absence of peri observational senolysis (count=0, extraovarian Farr) and for (iv) (Shin/SWAN). Extraovarian H1 for the KEEPS metrology lesson. Ovarian H0 for the Q0 arm. H0 as a prohibition of every future observational. H0 for Stein=KEEPS. It is not H2: computation was skipped.
Confidence: 0.76 that a SASP/T-p16 observational in −2/−1 does not validate senolytics; 0.18 that Faubion instantiates the Stein IL6 fork.

11. Competing hypothesis

L10-6-AR-H2 v1 — three rivals of the tube, not a breast that “already voted” independent inversion

Role: competing. Splits L10-6-HG-H2 v1. Contrary both to treating KEEPS as Stein and to killing a mammary timing object with p=0.0077 or copying it to ovary.

Falsifiable statement: after setting aside “observational validation of senolytics” as a name, one of these three —declared before the data— explains the residue of the tube and of Lue: (2a) in transition women, circulating SASP is stage/adiposity (Shin 17×binary menopause; SWAN IL-6/CRP × FMP; 0/28 × AMH in pre); (2b) oCEE moves GDF15/TNFR1/FAS by hepatic first pass / CEE metabolites, tE2 does not replicate, and that is not Stein nor senolysis; (2c) in indicated breast, the SASP–innate–EGFR–STAT3 programme predicts slower involution before FMP and faster after (NanoString, n=71), without that identifying ovarian Q0 or do(senolysis) — the p=0.0077 of n=14 is fragile spatial convergence, not the object.

Lineage: L10-6-HG-H2 v1 (weakened); L10-6-SCOPE-H5 v1; Harman PMID 25069991; Faubion PMID 32857481; Shin PMID 37610717 and 35583231; Lue PMID 42673763; Coppé PMID 21880712; L10-6-AR-C2; L10-6-AR-C3; L10-6-ED-C3.

Proposed mechanism: (2a) the STRAW/FMP calendar moves inflammation and adiposity without Q0. (2b) oral CEE induces hepatic acute-phase proteins; Mayo GDF15 is not osteoblast IL6. (2c) senescent–immune coupling changes sign in an indicated hormone-dependent organ; Coppé makes stall legal (arrest without effective SASP).

Predictions:

1. D0-ANALYTE-PARTITION: (2a) the mass of the 17 sits in 2022∪M, 0 in R × AMH-in-pre; (2b) the Harman CRP↑ / IL-6 quiet vs Faubion GDF15↓ with oCEE split is conserved; tE2 does not move IL-6; (2c) SASPcore × trajectory on n=71 remains on the paper, and the n=14 interface is not demanded as a kill.
2. D0-LUE-N71-PUBLIC: a null on binary pace is not estimable for (2c), not a refutation. A sign that inverts on the binary strengthens (2c) as a mammary object and is still not ovary. BMI/MHT independence is not voted without a DUA.
3. If SASPcore × trajectory collapses after circulating E2 or BMI (D0-LUE-N71-DUA), (2c) dies as independence and remains mammary spatial H5.
4. Concatenating −2/−1 with Farr +1 in a SASP × function meta-analyte produces mixed sign. Compatible with (2a) and (2c); it does not split them.
5. Relocating (2c) to non-indicated ovary is an ethics and category failure, not a victory.
6. Baker/Unity: an independent reanalysis or a second indicated organ is a replicate; the p of n=14 does not suffice.

Kill of (2a): a non-GDF15, non-NF-κB, non-CRP analyte, associated with AMH-in-pre after age+BMI with a CI that excludes the null and with a Q0 state.
Kill of (2b): tE2 moves Stein IL-6 without raising CRP, or GDF15 correlates with free E2 in the same woman.
Kill of (2c): SASPcore × years-from-menopause on n=71 collapses after E2/IL-6/BMI, or does not replicate in a second indicated organ.

Status: proposed_competing.
Maturity: H1 of literature for (2a) (Shin/SWAN) and for (2b) (Harman+Faubion, extraovarian). Weak mammary H1 for the transcriptomic sign of (2c). H0 for ligand independence, for n=14 as architecture, and for ovary. H0 as senolysis.
Confidence: 0.64 in (2a); 0.70 in (2b) as an oCEE readout; 0.48 in (2c) as transcriptomic inversion in breast; 0.22 that p=0.0077 n=14 is the object; 0.24 that (2c) survives E2/IL-6.

12. Translational hypothesis

L10-6-AR-HT1 v1 — the no-concatenation rule includes not nesting GDF15/IL-6/CRP as SASP and as a panel

Role: translational. Splits L10-6-HG-HT1 v1. HUMAN_QA_REQUIRED. Not a biomarker. Not a product.

Falsifiable statement (design rule, already in force): in adult women classified by STRAW+10, outside any user cohort, a parameter made of Farr CTx, KEEPS GDF15/TNFR1/FAS, Harman CRP, Shin SASP-as-stage, T-cell p16, flavonol Cmax, AMH, menstrual regularity, age at menopause, or a product called observational validation of senolytics that uses GDF15 or IL-6 or CRP at once as exposure and as covariate, will not be accepted as mediator of an organ event. AMH, by Weenen 2004, is labeled growing pool if it ever enters, not primordial endowment.

Empirical form (parked): none of those surrogates is run until AR-H1 or AR-H2 deliver an object. The comparator, if that object exists, is STRAW stage + adiposity ± a histological or primordial census named as such, without the same inflammatory as an arm of B, with competing risks. Beating GDF15 is tautological if B was GDF15. Beating STRAW and not the organ event is stage, not senolysis.

Lineage: L10-6-HG-HT1 v1; L10-6-AR-C4; Weenen PMID 14742691; Farr PMID 38956196; Harman PMID 25069991; Faubion PMID 32857481; Ruth PMID 34349265; L10-1-K10; L10-5-AR-C4.

Kill of the rule: it is marked H5 or biomarker, or Farr/KEEPS/AMH/Shin-stage is used as an ovarian effect of observational senolysis.
Kill of the empirics (when an object exists): an ovarian Q0-arm tracer, STRAW-stratified, out-of-sample beats stage + adiposity for an organ event without nesting B’s inflammatory.

Status: proposed, parked for human execution.
Maturity: H0. HUMAN_QA_REQUIRED. It is not H5.
Confidence: 0.74 in the rule (do not concatenate; do not nest inflammation); 0.08 in the complete empirical form.

13. Falsifiable predictions and kill criteria

14. Discriminating experiment

No new senolytic. No recruitment. Research, not a regimen for a woman. Nothing is executed at this stage except this turn’s esearch and the already-read inventory of GSE320321.

D0-ANALYTE-PARTITION — the Shin-17 × GDF15 cross is not an experiment

Mutually exclusive bins, written before any regression:

GDF15 is M (and 2022); it is labeled M and is not reused as residual. IL-6 is S, it does not enter HT1’s SASP panel. If the PDF does not list the 17, this step waits; it is not imputed.

D0-KEEPS-SPLIT — already run

Harman n=727 vs Faubion n=109, same trial, +1. A peri n is not recruited to rediscover it. Harman power d=0.30 o-CEE vs placebo ≈0.92 (gl=503): IL-6 quiet is not an n gap. Faubion tE2 n=34 vs placebo n=38: d=0.50 power ≈0.55; the tE2 null on GDF15 is not estimable as absence of effect.

D0-SHIN-RESIDUAL — AMH-in-pre only on bin R

n=147 pre already measured. gl=143 after age+BMI. Minimum kill of (2a) for a residual analyte: partial r=0.25 with a CI that excludes 0. Bonferroni-28 power ≈0.47 at r=0.25; k=8 ≈0.62. A p>0.05 on R remains not estimable, not “there is no ovarian arm.” If k residual=0, (2a) is strengthened and there is no AMH-in-pre to run. Do not recruit. AMH is labeled growing pool (Weenen).

D0-LUE-N71-PUBLIC — reconstruction, not the independence kill

GSE320321, n=71 with yfm. Public endpoint = binary pace. Prespecified model: logit(Progression) ∼ SASPcore + yfm + SASPcore×yfm + followup_interval. It is not relabeled a replicate of Fig. 4 F. BMI/MHT absent: independence of (2c) is not voted. n=71, r=0.30, power ≈0.73 unadj / ≈0.72 with 2 cov (gl=67, critical t=1.996) on a continuum the GSE does not deposit. A public null is not estimable for (2c). Unit = woman; 162 GSM are not n. Baker/Unity is recorded.

D0-LUE-N71-DUA — the only kill of (2c) independence

Only if 3a did not kill (2c) and a Mayo DUA with IRB exists. Minimum request: continuous pace, BMI, MHT or E2 if it exists. No slides; no ovary; no PHI toward Lua. yfm is not entered as an additional ligand covariate: it is already the axis.

n=14 satellite and closed gates

D0-LUE-N14-SPATIAL is not demanded. D0-OBS-PROXY-GATE stays closed: opening it now replicates Shin/SWAN/KEEPS and calls senolysis inverted do(oral CEE). G8 and empirical HT1 are not opened. Jin / GSE288940 are not reopened.

D0-ANALYTE-PARTITION (bins written; 17 unnamed)
        ↓
D0-KEEPS-SPLIT  already run (Harman CRP↑ IL-6 quiet vs Faubion GDF15↓ oCEE)
        ↓ peri is not recruited
D0-SHIN-RESIDUAL  PDF → names → AMH-in-pre ONLY in bin R
        ↓
D0-LUE-N71-PUBLIC  GSE320321, n=71 yfm, BINARY pace, without BMI/MHT
        ↓
   Does SASPcore×yfm already collapse in public?
        yes → (2c) weakens. No DUA. No Pharma of menopausal clearance.
        no → D0-LUE-N71-DUA (continuous pace + BMI + MHT/E2)
        ↓
   Does (2c) die after BMI/MHT?
        yes → Lue is spatial H5. AR-H1 closes the tube and this transcript.
        no → mammary timing object. Not ovary. Not senolysis. Not STRAW −2/−1.
              D0-OBS-PROXY-GATE stays closed.

15. Biomarkers and stratification

There is no validated biomarker. The following are research readouts, not biomarkers:

• STRAW+10: minimum human stratification, not a criterion of a trial this report does not authorize.
• Bins H/M/S/2022/R: metrology of already-measured analytes, not a companion panel.
• SASPcore × years-from-menopause in indicated breast: object of (2c), not an ovarian index.
• A histological primordial census named as such: comparator of AR-HT1 if an object someday exists.

T-cell p16, serum SASP, GDF15, IL-6, CRP, blood NAD, AMH, AFC, menstrual regularity, age at menopause, Farr CTx/P1NP, fisetin Cmax and the product “SASP × peri” cannot be presented as a single biomarker of ovarian senolysis, observational validation or longevity. SERPINE1 remains barred (L10-1-K3).

16. Individual variability

Expected heterogeneity includes STRAW stage (not age alone), adiposity/IAF (SWAN High-Decline 67.76% obese vs 4.48% Low-Rise), ancestry (Low-Rise enriched in Chinese/Japanese; High-Decline in Black women — a DAG node, not a LATAM license), inflammatory trajectory (Lee null vs SWAN mobile), ligand route (hepatic oCEE vs tE2), and —in breast— registered menopausal timing vs written STRAW. Human studies must distinguish:

• natural transition (−2/−1) versus Farr +1 (FSH>20, 62–88) and versus KEEPS 6–36 months post-FMP;
• binary pre/post (Shin) versus FMP (SWAN) versus registered years-from-menopause (Lue);
• indicated organ (breast, bone, adipose, lung) versus non-indicated ovary;
• sex: Liu is mixed; Hickson 7/9 males; Fang already showed systemic D+Q dimorphism;
• healthy user / flavonoid diet versus occupancy of A (H4 with no senolytic instance).

Participation of women is not equivalent to estimating modification by stage (L9-3-K9). Sixty postmenopausal women of Farr without ovary do not estimate STRAW −2. One hundred nine of Faubion on P4 do not estimate peri. Three Krishnakumar volunteers do not estimate ovarian occupancy. Seventy-one breast biopsies do not estimate ovarian Q0.

17. Pharma relevance and maturity

There is no nominated ovarian-senolysis target in peri. There is no modality. There is no indication in women’s health that this report authorizes. There is no trialable STRAW −2/−1 stratum. Maturity does not reach H5. HUMAN_QA_REQUIRED before any partnership conversation (L10-6-ED-C6).

Negative opportunity and conditional surveillance:

1. BCL2/SRC senolytics / D+Q. Farr: extraovarian RCT, 60 post, CTx P=0.611, enrollment by T-cell p16, zero ovary, zero STRAW −2/−1. Dasatinib has approved oncologic use; that does not make it ovarian A. A peri observational does not fill what D+Q did not move in +1 bone.
2. Fisetin. Farr arm cancelled. Krishnakumar Cmax n=3, no ovary. Ávila 2024: VCD + D+Q/fisetin, ovarian intervention-null. There is no peri active.
3. oCEE / tE2. Harman/Faubion are extraovarian do(ligand). oCEE raises CRP. It is not senolytic. Unity is not KEEPS. Ranking CEE against D+Q is category theatre.
4. “Senescent-cell clearance” in the menopausal window (Lue Implications; Baker/Unity). The object, if it survives D0-LUE-N71-DUA, is SASP–innate coupling in indicated breast, not ovarian Q0. Oncologic breast dual-use is not relabeled senolytic validation in peri. The p=0.0077 of n=14 is not a regulatory endpoint.
5. Serum SASP panel / GDF15 as companion. Shin: stage yes, AMH-in-pre no. Faubion: GDF15 moves with oCEE and does not correlate with E2. Nesting GDF15 as SASP and as comparator is forbidden (AR-HT1). It is not marked a biomarker.

H5 is not marked. Nothing is prescribed. There is no IND-enabling under this title.

18. Limitations

1. No step of the discriminant was executed except primary readings, the SOFT inventory of GSE320321 and this turn’s esearch. A report is not a β.
2. Shin 2023’s 17 remain unnamed. Bin R may be empty or may not exist until the PDF.
3. GSE320321 changes the estimand: binary pace, without BMI/MHT, without area/acini. Treating it as Fig. 4 F is the error the design names.
4. Power 0.73 at n=71 assumes r=0.30 on a continuous endpoint the GSE does not deposit. The 60/21 binary does not inherit that power. Critical t 1.996 (gl=67) is not a mammary or ovarian result.
5. Registered yfm is not E2. A DUA without E2 leaves (2c) independence partly not estimable. Pre 46 / Post 35 in GEO is registered menopause, not STRAW −2/−1.
6. Baker/Unity is not absolved by a GSE.
7. KEEPS is not peri. Transport of Harman/Faubion to −2/−1 is I.
8. Shin is Korea, cross-sectional, ~20-year gap pre vs post. Not LATAM. No blinded ICC/CV in the abstract.
9. SWAN n=1470 and n=779 are not the same women. Token STRAW=0.
10. p>0.05 of tE2, of CTx, of AMH-in-pre or of the n=14 interface does not establish equivalence.
11. Animal data (García, Gao, Ávila, Fang, ITP) do not authorize dose or intervention in people.
12. The bridge to longevity has no measured event, mediation or competing risks.
13. This report does not use user data. It proposes no product, persons or copy.
14. Greenland restricts this tube; it does not forbid a future A from entering the law in another design.

19. Conclusions

“Validating senolytics in perimenopausal women in an ethical observational study” names do(senolysis) on a graph that blood does not contain and a stage the primaries did not write. What it delivers is a serum SASP that tracks binary menopause and not AMH-in-pre (Shin); FMP inflammation split by adiposity (SWAN); a null extraovarian bone RCT that enrolls T-cell p16 (Farr); a ligand trial that raises CRP, leaves IL-6 quiet and lowers a Mayo multiplex that does not correlate with E2 (Harman/Faubion); a mammary inversion whose p of fourteen is not the object and whose GSE brings neither continuous pace nor BMI (Lue/GSE320321); and a PubMed count this turn reconfirms at zero.

The hypotheses that can be falsified now are not a protocol for women. They are AR-H1 (observing −2/−1 does not validate senolytics; the tube is not Stein=KEEPS; the clauses are voted separately), AR-H2 (stage/adiposity / oCEE liver / mammary inversion n=71 —voted separately), and AR-HT1 (organ mediation with Farr, KEEPS, Shin-stage, AMH or a product that nests GDF15/IL-6/CRP is not accepted). The smallest discriminant is not another peri n: it is a partition that leaves GDF15/CRP/IL-6 out of the residual, a KEEPS that already split Stein, an AMH-in-pre that is run only on what remains, and a tissue object the laboratory can touch without recruiting. Women’s longevity is not at stake in any of those endpoints.

20. References

1. Shin JW, Lee E, Han S, Choe SA, Jeon OH. Association of senescence-associated secretory phenotype proteins with ovarian reserve among middle-aged/older women. Menopause. 2023. DOI: 10.1097/GME.0000000000002238. PMID: 37610717. Abstract: n=223, 147 pre / 76 post; 17 SASP × menopause after age+BMI; 0/28 × AMH in pre. No PMC; names not listed.
2. Shin JW, Lee E, Han S, Choe SA, Jeon OH. Plasma Proteomic Signature of Cellular Senescence and Markers of Biological Aging Among Postmenopausal Women. Rejuvenation Res. 2022;25(3):141–148. DOI: 10.1089/rej.2022.0024. PMID: 35583231. n=76 post KoGES-CAVAS; GDF15, IGFBP-2, TNF-α × age; 13-protein signature named. Not an independent replicate of 2023.
3. El Khoudary SR, Chen X, Qi M, et al. hs-CRP and IL-6 trajectories anchored to FMP. J Clin Endocrinol Metab. 2025;110:e3566–e3576. DOI: 10.1210/clinem/dgaf175. PMID: 40123296. PMC12527447. hs-CRP n=1470; IL-6 n=779; token STRAW=0.
4. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition. J Clin Endocrinol Metab. 2009. DOI: 10.1210/jc.2008-0701. PMID: 19126626. PMC2682462. n=69; CRP/IL-6/TNF null pre→post; ΔIAF–ΔCRP r=0.56.
5. Lue JC, Stallings-Mann M, Hoskin T, et al. Menopausal timing and senescent–immune coupling in age-related lobular involution of the human breast: a longitudinal cohort study. eBioMedicine. 2026. DOI: 10.1016/j.ebiom.2026.106463. PMID: 42673763. PMC13560535. n=81; SASPcore × yfm n=71; Pre→Post 36 / Post→Post 35; pending pre R²=0.049 p=0.18; p=0.0077 n=14 (8/6); interface permutation p=0.37 / 0.26; GEO GSE320321; Zenodo 10.5281/zenodo.18775052; Baker/Unity COI written. Record reconfirmed 2026-10-04.
6. NCBI GEO GSE320321. Family SOFT, FTP 2026-10-04. Public on Feb 28 2026; Last-Modified 2026-09-11. 81 women, 162 GSM; years_from_menopause 71/81; binary pace Progression 60 / Stagnant 21; BMI/MHT absent.
7. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260. DOI: 10.7326/M14-0353. PMID: 25069991. NCT00154180. n=727; 6–36 months post-FMP; o-CEE 0.45 mg/d raises CRP and SHBG, not IL-6; t-E2 is not that pattern. Record reconfirmed 2026-10-04.
8. Faubion L, White TA, Peterson BJ, et al. Effect of menopausal hormone therapy on proteins associated with senescence and inflammation. Physiol Rep. 2020;8(16):e14535. DOI: 10.14814/phy2.14535. PMID: 32857481. PMC7453781. n=109 KEEPS; oCEE GDF15 −108 pg/mL p=.008, TNFR1 −234 p=.0006, FAS −1374 p<.0001; MIP1α not; no correlation with E1/E2. Record reconfirmed 2026-10-04.
9. Vongpatanasin W, Tuncel M, Wang Z, et al. Oral CEE doubles CRP; tE2 does not. J Clin Endocrinol Metab. 2003. PMID: 12706932.
10. Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024;30:2605–2612. DOI: 10.1038/s41591-024-03096-2. PMID: 38956196. PMC11705617. n=60; eligibility 60–90 / sample 62–88; CTx P=0.611; T3 p16_variant 5 n=21/39.
11. Liu Y, Sanoff HK, Cho H, et al. Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009. DOI: 10.1111/j.1474-9726.2009.00489.x. PMID: 19485966.
12. Coppé JP, Rodier F, Patil CK, et al. Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem. 2011;286:36396–36403. DOI: 10.1074/jbc.M111.257071. PMID: 21880712. PMC3196093. Not PMID 21372220.
13. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol. 1995;15:4971–4979. PMID: 7651415. PMC230744.
14. Ghisletti S, Meda C, Maggi A, Vegeto E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol. 2005;25:2957–2968. PMID: 15798185. PMC1069609.
15. Xing D, Oparil S, Yu H, et al. E2–ERβ raises IκBα in VSMC. PLoS One. 2012;7:e36890. PMID: 22606299. Not averaged with Ghisletti.
16. Pfeilschifter J, Köditz R, Pfohl M, Schatz H. Menopause and IL-1/IL-6/TNF; bone axis. Endocr Rev. 2002;23:90–119. PMID: 11844745. Review; does not vote senolysis.
17. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary. Mol Hum Reprod. 2004;10(2):77–83. DOI: 10.1093/molehr/gah015. PMID: 14742691.
18. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37–48. PMID: 9888278.
19. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. J Clin Endocrinol Metab. 2012;97:1159–1168. PMID: 22344196.
20. Ruth KS, Day FR, Hussain J, et al. Age at natural menopause: bone/T2D vs hormone-dependent cancer. Nature. 2021. DOI: 10.1038/s41586-021-03779-7. PMID: 34349265.
21. Ávila T, et al. VCD + D+Q/fisetin: senolytics did not lower induced ovarian senescence. Life Sci. 2024. DOI: 10.1016/j.lfs.2024.123073. PMID: 39307182.
22. García DN, et al. D+Q/fisetin, ovarian reserve and fertility in C57BL/6 females. GeroScience. 2024. PMID: 38358579.
23. Gao Y, et al. Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics. GeroScience. 2023;45:1775–1790. PMID: 36648735.
24. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. D+Q in DKD; N=9, 2 women. EBioMedicine. 2019. PMID: 31542391.
25. Justice JN, Nambiar AM, Tchkonia T, et al. D+Q in IPF; N=14, 2 women. EBioMedicine. 2019. PMID: 30616998.
26. Krishnakumar IM, et al. Fisetin PK; 3 women; aglycone Cmax ~0.035 µM; no ovary. J Nutr Sci. 2022. PMID: 36304817.
27. Harrison DE, Strong R, Reifsnyder P, et al. ITP; fisetin from 20 months; female median null. Geroscience. 2024. PMID: 38041783.
28. Fang Y, et al. D+Q vs fisetin; systemic dimorphism; ovary not measured. GeroScience. 2023. PMID: 37296266.
29. Sawyer MM, et al. Vaginal SASP × POP × pre/post, n=81. Aging Med (Milton). 2023. PMID: 37287674. Local extraovarian.
30. Shisler S, et al. THM × sleep: healthy-user analogy. Ann Epidemiol. 2015. PMID: 26358364.
31. Jin et al. Single-cell atlas of human ovarian aging. Nat Aging. 2025. PMID: 39578560. GSE202601. Young/old, not STRAW.
32. Isola JVV, et al. Mouse ovarian atlas; immune fraction ×2 at 9 months. Nat Aging. 2024. PMID: 38200272.
33. PubMed eutils esearch, 2026-10-04 (this turn): (senolytic OR dasatinib OR fisetin) AND (perimenopause OR STRAW OR "menopausal transition") AND (observational OR cohort OR trial) = 0; senolytic AND (STRAW+10 OR STRAW) = 0. G7 peri does not reopen.

Claims added in REPORT_EN: L10-6-REPORT-EN-C1.

Hypotheses touched: L10-6-AR-H1 v1, L10-6-AR-H2 v1, L10-6-AR-HT1 v1, L10-6-HG-H1 v1, L10-6-HG-H2 v1, L10-6-HG-HT1 v1, L10-6-SCOPE-H1 v1, L10-6-SCOPE-H2 v1, L10-6-MS-R1, D0-OBS-PROXY-GATE, D0-ANALYTE-PARTITION, D0-FORK-VS-INVERSION.

This report is scientific and does not constitute medical advice, prescription or authorization of use of dasatinib, quercetin, fisetin, navitoclax, CEE, transdermal estradiol or their combination. It is not written into memoria agentes/Lua Labs/reportes/. Promotion of the final report occurs only after QA.